SCHEMBL6170774

SCHEMBL6170774

CC(C)(C)c1ccc(C(=O)Nc2ccccc2C(=O)Nc2ccc3cn[nH]c3c2)cc1

nearest known ligand 0.63

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
NR1H4 Q96RI1 11/20 0.62
PPARG P37231 6/20 0.61
PPARA Q07869 6/20 0.61
NPC1 O15118 3/20 0.61
RAB9A P51151 3/20 0.61
SMN1; SMN2 Q16637 2/20 0.61
HPGD P15428 1/20 0.61
MAP4K4 O95819 1/20 0.60
CLK2 P49760 1/20 0.60
DYRK1A Q13627 1/20 0.60
SRPK1 Q96SB4 1/20 0.60
CLK4 Q9HAZ1 1/20 0.60
BTK Q06187 2/20 0.60
SYK P43405 1/20 0.60
DHPS P49366 1/20 0.58
PPARD Q03181 1/20 0.57
JAK2 O60674 2/20 0.54
JAK1 P23458 1/20 0.54
ALDH1A1 P00352 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6170667 0.88 MAP4K4 (0.56) NR1H4PPARGPPARANPC1RAB9A
SCHEMBL6169012 0.87 MAP4K4 (0.57) NR1H4NPC1RAB9ASMN1; SMN2HPGD
SCHEMBL6169511 0.87 NPC1 (0.68) NPC1RAB9ASMN1; SMN2HPGDMAP4K4
SCHEMBL6169107 0.86 BTK (0.59) NR1H4PPARGPPARANPC1RAB9A
SCHEMBL6169988 0.86 MAP4K4 (0.53) NR1H4PPARGPPARANPC1RAB9A
SCHEMBL6170952 0.85 NPC1 (0.56) NR1H4PPARGPPARANPC1RAB9A
SCHEMBL6171764 0.85 RAB9A (0.53) NR1H4PPARGPPARANPC1RAB9A
SCHEMBL6168129 0.84 MAP4K4 (0.54) NR1H4NPC1RAB9ASMN1; SMN2HPGD
SCHEMBL6170427 0.84 NPC1 (0.70) NPC1RAB9ASMN1; SMN2HPGDMAP4K4
SCHEMBL6169264 0.84 HPGD (0.55) NR1H4NPC1RAB9ASMN1; SMN2HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6372759-B1 BLOOD COAGULATION FACTOR XA FOR MAMMALS ELI LILLY AND COMPANY 2002-04-16 US claimed
EP-1019045-B1 ANTITHROMBOTIC AGENTS LILLY CO ELI (US) 2005-06-08 EP disclosed
US-20030078431-A1 Antithrombotic agents BEIGHT DOUGLAS WADE (US) 2003-04-24 US disclosed
US-6500851-B2 ANTICOAGULANT IN MAMMLS ELI LILLY AND COMPANY 2002-12-31 US disclosed
US-20020173518-A1 Antithrombotic agents BEIGHT DOUGLAS WADE (US) 2002-11-21 US disclosed
EP-1019045-A4 ANTITHROMBOTIC AGENTS LILLY CO ELI (US) 2002-07-03 EP disclosed
US-6372759-B1 BLOOD COAGULATION FACTOR XA FOR MAMMALS ELI LILLY AND COMPANY 2002-04-16 US disclosed
EP-1019045-A1 ANTITHROMBOTIC AGENTS ELI LILLY AND COMPANY (US) 2000-07-19 EP disclosed
WO-1999000128-A9 ANTITHROMBOTIC AGENTS LILLY CO ELI (US) 1999-08-05 WO disclosed
WO-1999000128-A1 ANTITHROMBOTIC AGENTS ELI LILLY AND COMPANY (US) 1999-01-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020173518-A1 Antithrombotic agents SERPINC1, TFPI, F11 NR1H4 1884/4885PPARG 3664/4885PPARA 3821/4885
US-20030078431-A1 Antithrombotic agents SERPINC1, TFPI, F11 NR1H4 1884/4885PPARG 3664/4885PPARA 3821/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.